Labcorp Holdings EVP granted options, RSUs

Labcorp Holdings Inc. executive Megan D. Bailey reported equity awards received on February 10, 2026.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Megan D. Bailey reported equity awards received on February 10, 2026. She was granted 3,300 non-qualified stock options with a $284.5 exercise price under the 2025 Omnibus Incentive Plan, vesting in three equal annual installments starting on that grant date.

She was also granted 1,100 Restricted Stock Units, each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. After this grant, she directly holds 3,300 stock options and 3,230 Restricted Stock Units.

Insider Trade Summary

Grant/Award: 4,400 shares

Grant/Award 2 txns

Insider Bailey Megan D.

Role EVP, Pres, Central Labs & Intl

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Options	3,300	$0.00	$0.00
Grant/Award	Restricted Stock Unit	1,100	$0.00	$0.00

Holdings After Transaction: Non-qualified Stock Options — 3,300 contracts (Direct); Restricted Stock Unit — 3,230 contracts (Direct)

Footnotes (5)

F1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.
F2. The option vests in three equal annual installments beginning on the date reflected in this column.
F3. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
F4. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.
F5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Labcorp (LH) report for Megan D. Bailey?

Labcorp reported that EVP Megan D. Bailey received grants of 3,300 non-qualified stock options and 1,100 Restricted Stock Units on February 10, 2026. These awards are part of her equity compensation and vest over multiple years under the company’s incentive plan.

How many stock options were granted to Labcorp (LH) executive Megan D. Bailey?

Megan D. Bailey was granted 3,300 non-qualified stock options at a $284.5 exercise price on February 10, 2026. These options vest in three equal annual installments, beginning on the same date as the grant, under Labcorp’s 2025 Omnibus Incentive Plan.

What Restricted Stock Units did Megan D. Bailey receive from Labcorp (LH)?

She received 1,100 Restricted Stock Units on February 10, 2026. Each unit represents the right to receive one share of Labcorp common stock, vesting in three equal annual installments starting on February 10, 2027, aligning her compensation with long-term shareholder interests.

When do Megan D. Bailey’s Labcorp (LH) stock options and RSUs vest?

Her 3,300 stock options vest in three equal annual installments beginning on February 10, 2026. The 1,100 Restricted Stock Units vest in three equal annual installments starting on February 10, 2027, creating a staggered, multi-year vesting schedule for these awards.

How many Labcorp (LH) Restricted Stock Units does Megan D. Bailey now hold?

Following the February 10, 2026 grant, Megan D. Bailey beneficially owns 3,230 Restricted Stock Units. This figure reflects the aggregate number of RSUs held and represents her contingent right to receive the same number of Labcorp common shares as they vest over time.

What is the exercise price and term of Megan D. Bailey’s Labcorp (LH) options?

Her non-qualified stock options have a $284.5 exercise price per share and expire on February 9, 2036. They were granted on February 10, 2026 and vest in three equal annual installments beginning on the grant date, providing a long-dated equity incentive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/12/2026 - 03:34 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bailey Megan D.

(Last)

(First)

(Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON

27215

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Pres, Central Labs & Intl

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Options⁽¹⁾	$284.5	02/10/2026		A		3,300		02/10/2027⁽²⁾	02/09/2036	Common Stock	3,300	$0	3,300	D
Restricted Stock Unit	⁽³⁾	02/10/2026		A		1,100		⁽⁴⁾	⁽⁴⁾	Common Stock	1,100	$0	3,230⁽⁵⁾	D

Explanation of Responses:

1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.

2. The option vests in three equal annual installments beginning on the date reflected in this column.

3. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

4. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.

5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Megan D. Bailey	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR